Chris Long and his wife, Janet, were thrilled when he became the first patient at MUSC Health to receive the Alzheimer’s drug ...

Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...

Kevin Smith, a resident of Clifton Park, is experiencing the benefits of a recently approved Alzheimer's drug, Leqembi, as he ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages.

RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for ...

Acquisitions involving innovator drugs have grown year-on-year with total deal value increasing eight-fold to almost $18 ...

Microsoft co-founder Bill Gates reflects on his father's Alzheimer's battle and expresses optimism about advancements in ...

Diagnosing Alzheimer’s is difficult, and precise biomarkers are needed to assist physicians in making accurate assessments, ...

Neither Kisunla (donanemab, Eli Lilly & Co. Inc.) or Leqembi (lecanemab, Eisai Co. Ltd.) “demonstrate sufficient benefit to justify their high cost, including the cost of administering them,” the ...

Digging into a prespecified analysis for the mid-stage study, INmune Bio identified some clinical and biological benefits of ...

Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.